Abbott Korea launched 'iDECIDE' anti-obesity campaign

Published: 2004-08-11 06:58:00

Updated: 2004-08-11 06:58:00

Abbott Korea, which has marketed its weight loss drug Reductil since 2001, has announced that it is starting a new anti-obesity online campaign entitled 'iDECIDE', with an aim to publicize the importance of obese patients' strong will in the course of treatment and deliver a message from healthcare professionals for correct obesity management.

The most recent WHO recommendations for dietary ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.